1. Home
  2. SSP vs MDWD Comparison

SSP vs MDWD Comparison

Compare SSP & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo E.W. Scripps Company (The)

SSP

E.W. Scripps Company (The)

HOLD

Current Price

$3.95

Market Cap

395.2M

Sector

Industrials

ML Signal

HOLD

Logo MediWound Ltd.

MDWD

MediWound Ltd.

HOLD

Current Price

$18.68

Market Cap

238.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SSP
MDWD
Founded
1878
2000
Country
United States
Israel
Employees
N/A
N/A
Industry
Broadcasting
Medicinal Chemicals and Botanical Products
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
395.2M
238.5M
IPO Year
1988
2014

Fundamental Metrics

Financial Performance
Metric
SSP
MDWD
Price
$3.95
$18.68
Analyst Decision
Buy
Strong Buy
Analyst Count
2
2
Target Price
$5.50
$37.50
AVG Volume (30 Days)
986.5K
82.4K
Earning Date
11-06-2025
11-20-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,318,706,000.00
$20,932,000.00
Revenue This Year
N/A
$15.89
Revenue Next Year
$9.11
$25.33
P/E Ratio
N/A
N/A
Revenue Growth
N/A
6.15
52 Week Low
$1.36
$14.14
52 Week High
$4.98
$22.51

Technical Indicators

Market Signals
Indicator
SSP
MDWD
Relative Strength Index (RSI) 44.90 53.42
Support Level $3.88 $18.55
Resistance Level $4.98 $18.96
Average True Range (ATR) 0.32 0.53
MACD -0.14 -0.00
Stochastic Oscillator 5.36 27.38

Price Performance

Historical Comparison
SSP
MDWD

About SSP E.W. Scripps Company (The)

The E W Scripps Co is a media enterprise with interests in local and national media brands. It owns and operates a collection of daily and community newspapers in medium-sized cities in the southern and western portions of the United States. The company's operating segment includes Local Media, Scripps Networks, and Other. It generates maximum revenue from the Local Media segment. The Local Media segment includes local broadcast stations and their related digital operations.

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

Share on Social Networks: